If these trials confirm the findings, benralizumab could become the first new therapy approved for eosinophilic exacerbations ...

Ensifentrine is a promising supplementary therapeutic option in the management of chronic obstructive pulmonary disease (COPD), according to systematic review and meta-analysis findings published in ...

The researchers hope it will pave the way for new treatment ... Aug. 22, 2024 — Managing hard-to-treat respiratory illnesses like asthma and pulmonary fibrosis just got easier if a new drug ...

Tezepelumab did not significantly decrease moderate or severe COPD exacerbations compared with placebo, the COURSE trial found.

Inc., an integrated clinical-stage biopharmaceutical company dedicated to developing inhaled medicines, today announced the ...

Ohtuvayre showed significant improvement in lung function by 12 weeks. Follow-up analyses showed that Ohtuvayre had long-term ...

Based on a survey of cardiologist and pulmonologists treating patients for pulmonary arterial hypertension (PAH), analysts at ...

Shares in Keros Therapeutics fell sharply Wednesday morning after it said it halted trials of its treatment for pulmonary hypertension after finding adverse health effects in patients trialing the ...

Four-month regimen recommended for drug-susceptible TB and six-month regimen recommended for drug-resistant TB ...